Glumetinib for tablet

Yilong Wu, M.D.

Yilong Wu, MD

This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.

Study to Evaluate the Safety and Anti-tumor Activity of SCC244

A Phase I Trial to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of SCC244 in Subjects With Advanced Solid Tumors

To evaluate the DLT in patients with advanced solid tumor

To evaluate the MTD in patients with advanced solid tumor

To evaluate the BED in patients with advanced solid tumor

To evaluate the ORR in patients with advanced solid tumor in Ib

Haihe Biopharma Co., Ltd.

25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)

JIN LI, M.D

Jin Li, M.D.

This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration

A Phase I Study of SCC244

A Multi-center, Open-label, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of SCC244 in Advanced Solid Tumors Patients With c-MET Alteration

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study to Evaluate the Safety and Anti-tumor Activity of SCC244	NCT03466268	Advanced Solid ...	Glumetinib for ...	18 Years -	Haihe Biopharma Co., Ltd.
A Phase I Study of SCC244	NCT03457532	Advanced Solid ...	Glumetinib for ...	18 Years - 70 Years	Haihe Biopharma Co., Ltd.

Spots Global Cancer Trial Database for glumetinib for tablet